A carregar...
Repurposing EGFR inhibitor utility in colorectal cancer in mutant APC and TP53 subpopulations
BACKGROUND: EGFR is a major therapeutic target for colorectal cancer (CRC). Currently, extended RAS/RAF testing identifies only non-responders to EGFR inhibitors (EGFRi). We aimed to develop a mutation signature that further refines drug-sensitive subpopulations to improve EGFRi outcomes. METHODS: A...
Na minha lista:
| Publicado no: | Cancer Epidemiol Biomarkers Prev |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7845290/ https://ncbi.nlm.nih.gov/pubmed/31015202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-18-1383 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|